Q3 EPS Forecast for Mirum Pharmaceuticals Reduced by Analyst

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Research analysts at HC Wainwright lowered their Q3 2027 EPS estimates for Mirum Pharmaceuticals in a report released on Monday, October 12th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.27 for the quarter, down from their previous forecast of $0.35. HC Wainwright has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.31) per share.

A number of other equities research analysts have also weighed in on MIRM. JPMorgan Chase & Co. raised their price objective on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Royal Bank Of Canada boosted their target price on shares of Mirum Pharmaceuticals from $135.00 to $155.00 and gave the stock an “outperform” rating in a research note on Thursday, October 8th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a report on Monday, June 15th. Finally, Wall Street Zen cut Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $146.12.

Mirum Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ:MIRM opened at $86.06 on Tuesday. Mirum Pharmaceuticals has a 52 week low of $63.23 and a 52 week high of $130.00. The company’s 50 day moving average is $94.71 and its two-hundred day moving average is $100.95. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. The company has a market cap of $5.59 billion, a PE ratio of -5.91 and a beta of 0.61.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The firm had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same quarter last year, the firm earned ($0.12) EPS. The company’s revenue was up 37.9% on a year-over-year basis.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 40,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the transaction, the senior vice president directly owned 1,274 shares in the company, valued at $127,400. This represents a 96.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the sale, the chief executive officer directly owned 194,440 shares in the company, valued at approximately $19,187,339.20. The trade was a 13.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 98,499 shares of company stock worth $9,797,834 over the last three months. Insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new stake in Mirum Pharmaceuticals in the second quarter valued at $27,000. Summit Securities Group LLC acquired a new position in Mirum Pharmaceuticals in the first quarter valued at $42,000. Quantbot Technologies LP acquired a new position in Mirum Pharmaceuticals in the second quarter valued at $44,000. State of Wyoming acquired a new position in Mirum Pharmaceuticals in the second quarter valued at $52,000. Finally, Fifth Third Bancorp purchased a new position in shares of Mirum Pharmaceuticals during the first quarter worth about $56,000.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Phase 3 EXPAND study met its primary endpoint. Mirum said LIVMARLI demonstrated a statistically significant treatment benefit in patients with ultra-rare cholestatic liver diseases, including biliary atresia. The result strengthens the case for expanding LIVMARLI’s use beyond its current indications. Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study
• Positive Sentiment: Mirum plans to submit an FDA filing in 2027. A regulatory application based on the positive results provides a potential future catalyst, although commercialization remains dependent on regulatory review and approval. Mirum Reports Positive Phase 3 LIVMARLI Results
• Positive Sentiment: Analysts became more bullish. Citigroup raised its price target from $160 to $184 and assigned a Buy rating, while HC Wainwright increased its target from $195 to $200 and maintained a Buy rating. The targets imply substantial upside from the referenced share price and indicate increased confidence in Mirum’s pipeline and growth prospects.
• Neutral Sentiment: Mirum hosted an investor call to discuss the EXPAND topline results, giving investors additional details on the trial and the planned regulatory path. Mirum Investor Call Announcement
• Negative Sentiment: The FDA filing is not expected until 2027, leaving execution, regulatory and commercialization risks before the potential indication can generate revenue.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.